CLAIMS

1. Use of an antibody or an antigen-binding fragment thereof which specifically binds PCSK9 to a subject in need thereof, and

an HMG-CoA reductase inhibitor to said subject for the manufacture of a medicament for treating a disease or condition in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof is administered in a dosage amount ranging from about 40 mg to 500 mg, and

wherein the HMG-CoA reductase inhibitor is preferably administered in a dosage amount ranging from 0.05 mg to 100 mg.

2. An antibody or an antigen-binding fragment thereof which specifically binds proprotein convertase subtilisin/kexin type (PCSK9) for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof is for administration in a dosage amount ranging from about 40 mg to 500 mg, and

wherein the antibody or antigen-binding fragment thereof is further for administration in combination with an HMG-CoA reductase inhibitor at a dosage amount ranging from about 0.05 mg to 100 mg.

3. The use or the antibody of any one of claims 1-2, wherein the disease or condition in which PCSK9 expression or activity causes an impact is selected from the group consisting of: elevated total cholesterol levels, elevated low-density lipoprotein cholesterol (LDL-C) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular disease, hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, and hypercholesteremia which is uncontrolled by statins.

4. The use or the antibody of any one of claims 1 to 3, wherein the HMG-CoA reductase inhibitor is administered three times per day, twice per day, once per day, every other day, every third day, every fourth day, every fifth day, or every sixth day, every week, every other week, every third week, or every fourth week or every month.

5. The use or the antibody of any one of claims 1 to 4, wherein the HMG-CoA reductase inhibitor is a statin selected from the group consisting of cerivastatin simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, and pravastatin.

6. The use or the antibody of any one of claims 1 to 5, wherein the antibody or antigen-binding fragment thereof is administered to the subject every other week or every 4 weeks.

7. The use or the antibody of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof is administered in a dosage selected from the group consisting of 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg.

8. The use or the antibody of any one of claims 1 to 7, wherein the antibody or the antigen-binding fragment thereof is characterized by one or more of the following:

(i) capable of reducing serum total cholesterol at least about 25 to about 35% and sustaining the reduction over at least a 24 day period relative to a predose level;

(ii) capable of reducing serum LDL cholesterol at least about 65-80% and sustaining the reduction over at least a 24 day period relative to a predose level;

(iii) capable of reducing serum triglyceride at least about 25-40% relative to predose level;

(iv) achieves one or more of (i)-(iii) without reducing serum HDL cholesterol or reducing serum HDL cholesterol no more than 5% relative to predose level; and

(v) achieves one or more of (i)-(iii) with little or no measurable effect on liver function, as determined by ALT and AST measurements.

9. The use or the antibody of any one of claims 1 to 8, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR sequences from the HCVR and LCVR amino acid sequence pair having SEQ ID NOs: 90/92.

10. An article of manufacture comprising

(a) a packaging material;

(b) an antibody or an antigen-binding fragment thereof which specifically binds PCSK9; and

(c) a label or packaging insert contained within the packaging material indicating the treatment of patients with said antibody or antigen-binding fragment thereof together with the administration of a statin.

11. Use of an antibody or an antigen-binding fragment thereof which specifically binds PCSK9 to a subject in need thereof for the manufacture of a medicament for treating a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the subject in need thereof falls into one or more of the following groups of subjects:

(i) subjects having a serum LDL cholesterol (LDL-C) level of at least 100 mg/dL,

(ii) subjects having a serum HDL-C level of less than 40 mg/dL;

(iii) subjects having a serum cholesterol level of at least 200 mg/dL;

(iv) subjects having a serum triacylglycerol level of at least 150 mg/dL, wherein said triacylglycerol level is determined after fasting for at least 8 hours;

(v) subjects being at least 35 years old;

(vi) subjects younger than 75 years old;

(vii) subjects having a BMI of 25 or more;

(vii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 30 mg/dL relative to predose level; and

(viii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 20% relative to predose level.

12. An antibody or an antigen-binding fragment thereof which specifically binds PCSK9 (proprotein convertase subtilisin/kexin type 9) for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof is for administration to a subject falling at least into one of the following groups of subjects:

(i) subjects having a serum LDL cholesterol (LDL-C) level of at least 100 mg/dL,

(ii) subjects having a serum HDL-C level of less than 40 mg/dL;

(iii) subjects having a serum cholesterol level of at least 200 mg/dL;

(iv) subjects having a serum triacylglycerol level of at least 150 mg/dL, wherein said triacylglycerol level is determined after fasting for at least 8 hours;

(v) subjects being at least 35 years old;

(vi) subjects younger than 75 years old;

(vii) subjects having a BMI of 25 or more;

(vii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 30 mg/dL relative to predose level; and

(viii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 20% relative to predose level.

13. The use or the antibody of any one of claims 11-12, wherein the disease or condition in which PCSK9 expression or activity causes an impact is selected from the group consisting of: elevated total cholesterol levels, elevated low-density lipoprotein cholesterol (LDL-C) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular disease, hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, and hypercholesteremia which is uncontrolled by statins.

14. The use or the antibody of any one of claims 11 to 13, wherein the HMG-CoA reductase inhibitor is administered three times per day, twice per day, once per day, every other day, every third day, every fourth day, every fifth day, or every sixth day, every week, every other week, every third week, or every fourth week or every month.

15. The use or the antibody of any one of claims 11 to 14, wherein the HMG-CoA reductase inhibitor is a statin selected from the group consisting of cerivastatin simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin, and pravastatin.

16. The use or the antibody of any one of claims 11 to 15, wherein the antibody or antigen-binding fragment thereof is administered to the subject every other week or every 4 weeks.

17. The use or the antibody of any one of claims 11 to 16, wherein the antibody or antigen-binding fragment thereof is administered in a dosage selected from the group consisting of 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg.

18. The use or the antibody of any one of claims 11 to 17, wherein the antibody or the antigen-binding fragment thereof is characterized by one or more of the following:

(i) capable of reducing serum total cholesterol at least about 25 to about 35% and sustaining the reduction over at least a 24 day period relative to a predose level;

(ii) capable of reducing serum LDL cholesterol at least about 65-80% and sustaining the reduction over at least a 24 day period relative to a predose level;

(iii) capable of reducing serum triglyceride at least about 25-40% relative to predose level;

(iv) achieves one or more of (i)-(iii) without reducing serum HDL cholesterol or reducing serum HDL cholesterol no more than 5% relative to predose level; and

(v) achieves one or more of (i)-(iii) with little or no measurable effect on liver function, as determined by ALT and AST measurements.

19. The use or the antibody of any one of claims 11 to 18, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR sequences from the HCVR and LCVR amino acid sequence pair having SEQ ID NOs: 90/92.

20. An article of manufacture comprising

(a) a packaging material;

(b) an antibody or an antigen-binding fragment thereof which specifically binds PCSK9; and

(c) a label or packaging insert contained within the packaging material indicating that patients receiving treatment with said antibody or antigen-binding fragment can be treated for a disease or condition selected from the group consisting of hypercholesterolemia, hyperlipidemia, dyslipidemia, atherosclerosis and cardiovascular diseases, and further indicating that the patients fall into one or more of the following groups of subjects:

(i) subjects having a serum LDL cholesterol (LDL-C) level of at least 100 mg/dL,

(ii) subjects having a serum HDL-C level of less than 40 mg/dL;

(iii) subjects having a serum cholesterol level of at least 200 mg/dL;

(iv) subjects having a serum triacylglycerol level of at least 150 mg/dL, wherein said triacylglycerol level is determined after fasting for at least 8 hours;

(v) subjects being at least 35 years old;

(vi) subjects younger than 75 years old;

(vii) subjects having a BMI of 25 or more;

(vii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 30 mg/dL relative to predose level; and

(viii) subjects in which the administration of said antibody or antigen-binding fragment thereof leads to a reduction in the serum LDL-C level by at least 20% relative to predose level.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A pharmaceutical composition comprising 40 to 500 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) together with a pharmaceutically acceptable excipient or carrier for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two or four weeks, and wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs: 76, 78, and 80 and the three light chain CDRs set forth in SEQ ID NOs: 84, 86, and 88.

2. The use of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) for the manufacture of a pharmaceutical composition for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the composition comprises a pharmaceutically acceptable excipient or carrier, wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two or four weeks, and wherein the antibody or antigen-binding fragment thereof comprises the three heavy chain CDRs set forth in SEQ ID NOs: 76, 78, and 80 and the three light chain CDRs set forth in SEQ ID NOs: 84, 86, and 88.

3. The pharmaceutical composition according to claim 1, or use according to claim 2, wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable region (HCVR) amino acid sequence and the light chain variable region (LCVR) amino acid sequence set forth in SEQ ID NOs: 90 and 92, respectively, and wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact.

4. The pharmaceutical composition of claim 1 or 3, or use according to claim 2 or 3, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the disease or condition in

which PCSK9 expression or activity causes an impact is selected from the group consisting of elevated total cholesterol levels, elevated non-high-density lipoprotein (HDL) cholesterol levels, elevated low-density lipoprotein (LDL-C) levels, elevated apolipoprotein B100 (ApoB100) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular diseases, coronary heart disease (CHD), hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, non-familial hypercholesterolemia, heterozygous familial hypercholesterolemia (heFH), hypercholesteremia that is uncontrolled by statins, and hypercholesterolemia that is resistant to statins.

5. The pharmaceutical composition according to any one claims 1, 3 or 4, or the use according to any one of claims 2 to 4, wherein the composition is for use in the treatment of a disease or condition in a subject in which PCSK9 expression or activity causes an impact and wherein said subject falls into at least one of the following groups of subjects:

(i) subjects having a serum LDL cholesterol (LDL-C) level of at least 100 mg/dL,

(ii) subjects having a serum HDL-C level of less than 40 mg/dL;

(iii) subjects having a serum cholesterol level of at least 200 mg/dL; and

(iv) subjects having a serum triacylglycerol level of at least 150 mg/dL, wherein said triacylglycerol level is determined after fasting for at least 8 hours.

6. The pharmaceutical composition according to any one of claims 1 or 3 to 5, or use according to any one of claims 2 to 5, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and the composition comprises about 40 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350mg, 400 mg, 450 mg or 500 mg of the antibody or antigen-binding fragment thereof.

7. The pharmaceutical composition or use according to claim 6, comprising about 75 mg of the antibody or antigen-binding fragment thereof, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

8. The pharmaceutical composition or use according to claim 6, comprising about 150 mg of the antibody or antigen-binding fragment thereof, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

9. The pharmaceutical composition or use according to claim 6, comprising about 150 mg of the antibody or antigen-binding fragment thereof, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

10. The pharmaceutical composition or use according to claim 6, comprising about 300 mg of the antibody or antigen-binding fragment thereof, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

11. The pharmaceutical composition according to any one of claims 1 or 3 to 5, or use according to any one of claims 3 to 5, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition comprises the antibody or antigen-binding fragment thereof as a liquid formulation, wherein the liquid formulation is an injection solution comprising about 40 mg to about 500 mg of the antibody or antigen-binding fragment thereof per 1 ml volume.

12. The pharmaceutical composition or use according to claim 11, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the injection solution comprises

about 40 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of the antibody or antigen-binding fragment thereof per 1 ml volume.

13. The pharmaceutical composition or use according to claim 12, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the injection solution comprises 75 mg of the antibody or antigen-binding fragment thereof per 1 ml volume and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

14. The pharmaceutical composition or use according to claim 12, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the injection solution comprises 150 mg of the antibody or antigen-binding fragment thereof per 1 ml volume and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

15. The pharmaceutical composition or use according to claim 12, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the injection solution comprises 150 mg of the antibody or antigen-binding fragment thereof per 1 ml volume and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

16. The pharmaceutical composition or use according to claim 12, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the injection solution comprises 300 mg of the antibody or antigen-binding fragment thereof per 1 ml volume and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

17. The pharmaceutical composition according to any one of claims 1 or 3 to 5, or use according to any one of claims 2 to 5, wherein the composition is for use in the treatment

of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the pharmaceutical composition is comprised in a unit dosage form and wherein the unit dosage form comprises about 40 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, or 500 mg of the antibody or antigen-binding fragment thereof.

18. The pharmaceutical composition or use according to claim 17, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the unit dosage form comprises 75 mg of the antibody or antigen-binding fragment thereof and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

19. The pharmaceutical composition or use according to claim 17, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the unit dosage form comprises 150 mg of the antibody or antigen-binding fragment thereof and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks.

20. The pharmaceutical composition or use according to claim 17, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the unit dosage form comprises 150 mg of the antibody or antigen-binding fragment thereof and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

21. The pharmaceutical composition or use according to claim 17, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the unit dosage form comprises 300 mg of the antibody or antigen-binding fragment thereof and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks.

22. The pharmaceutical composition according to any one of claims 1 or 3 to 21, or use according to any one of claims 2 to 21, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the pharmaceutical composition is in a hermetically sealed container selected from the group consisting of a vial, a sachet, a pre-filled syringe, a pre-filled autoinjector, a cartridge for a reusable syringe, and an applicator.

23. The pharmaceutical composition according to any one of claims 1 or 3 to 22, or the use according to any one of claims 2 to 22, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof by subcutaneous injection.

24. The pharmaceutical composition according to any one of claims 1 or 3 to 23, or use according to any one of claims 2 to 23, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the antibody or antigen-binding fragment thereof binds an epitope comprising one or more of amino acid residues at positions 238, 153, 159, and 343 of hPCSK9 (SEQ ID NO:755).

25. The pharmaceutical composition according to any one of claims 1 or 3 to 24, or use according to any one of claims 2 to 24, wherein the composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact and wherein the formulation of the composition according to a dosing regime providing said antibody or antigen-binding fragment thereof achieves one or more of the following:

(a) reduction of LDL-C of at least -60 % to at least -75% relative to a predose level with a sustained reduction over at least a 14 day-period upon administering to a subject a dose of 150 mg every two weeks;

(b) reduction of LDL-C of at least -50 % to -75% relative to a predose level with a sustained reduction over at least a 28 day-period upon administering to a subject a dose of 300 mg every four weeks;

(c) increase of serum HDL cholesterol levels of at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5% or at least 5.5% relative to a predose level upon administering to a subject a dose of 150 mg every two weeks;

(d) increase of one or more of: total-cholesterol levels, ApoB levels, non HDL-C levels, and Apo-B/ApoA-1 ratio.

26. A pharmaceutical composition comprising 75 mg of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9,

or the use of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9 for the manufacture of a pharmaceutical composition comprising 75 mg of said antibody or said antigen-binding fragment thereof, said pharmaceutical composition for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable region (HCVR) amino acid sequence and the light chain variable region (LCVR) amino acid sequence set forth in SEQ ID NOs: 90 and 92, respectively,

wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks in a 1 ml injection solution,

and wherein the disease or condition is selected from the group consisting of elevated total cholesterol levels, elevated non-high-density lipoprotein (HDL) cholesterol levels, elevated low-density lipoprotein (LDL-C) levels, elevated apolipoprotein B100 (ApoB100) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular diseases, coronary heart disease (CHD), and hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, non-familial hypercholesterolemia, heterozygous familial hypercholesterolemia (heFH), and hypercholesteremia that is uncontrolled by statins.

27. A pharmaceutical composition comprising 150 mg of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9,

or the use of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9 for the manufacture of a pharmaceutical composition comprising 150 mg of said antibody or said antigen-binding fragment thereof, said pharmaceutical composition for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable region (HCVR) amino acid sequence and the light chain variable region (LCVR) amino acid sequence set forth in SEQ ID NOs: 90 and 92, respectively,

wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every two weeks or every four weeks in a 1 ml injection solution,

and wherein the disease or condition is selected from the group consisting of elevated total cholesterol levels, elevated non-high-density lipoprotein (HDL) cholesterol levels, elevated low-density lipoprotein (LDL-C) levels, elevated apolipoprotein B100 (ApoB100) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular diseases, coronary heart disease (CHD), hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, non-familial hypercholesterolemia, heterozygous familial hypercholesterolemia (heFH), and hypercholesteremia that is uncontrolled by statins.

28. A pharmaceutical composition comprising 300 mg of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9,

or the use of an antibody or an antigen-binding fragment thereof which specifically binds hPCSK9 for the manufacture of a pharmaceutical composition comprising 300 mg of said antibody or said antigen-binding fragment thereof, said

pharmaceutical composition for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact,

wherein the antibody or antigen-binding fragment thereof comprises the heavy chain variable region (HCVR) amino acid sequence and the light chain variable region (LCVR) amino acid sequence set forth in SEQ ID NOs: 90 and 92, respectively,

wherein the pharmaceutical composition is formulated according to a dosing regime providing said antibody or antigen-binding fragment thereof about every four weeks in a 1 ml injection solution,

and wherein the disease or condition is selected from the group consisting of elevated total cholesterol levels, elevated non-high-density lipoprotein (HDL) cholesterol levels, elevated low-density lipoprotein (LDL-C) levels, elevated apolipoprotein B100 (ApoB100) levels, hyperlipidemia, dyslipidemia, atherosclerosis, cardiovascular diseases, coronary heart disease (CHD), hypercholesterolemia, primary hypercholesterolemia, familial hypercholesterolemia, non-familial hypercholesterolemia, heterozygous familial hypercholesterolemia (heFH), and hypercholesteremia that is uncontrolled by statins.

29. The pharmaceutical composition according to any one of claims 1 or 3 to 28, or the use according to any one of claims 2 to 28, wherein said pharmaceutical composition is for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, and wherein said pharmaceutical composition or use is substantially as hereinbefore described.